Sara V Little

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIMS Standard triple therapy remains the recommended first line treatment for Helicobacter pylori in New Zealand. The real eradication rate achieved in busy hospital clinics may be different from data obtained from clinical trials outside of New Zealand. METHODS One hundred and thirty patients with proven H pylori infection (by at least two tests) were(More)
BACKGROUND Peanut oral immunotherapy is a promising approach to peanut allergy, but reactions are frequent, and some patients cannot be desensitized. The anti-IgE medication omalizumab (Xolair; Genentech, South San Francisco, Calif) might allow more rapid peanut updosing and decrease reactions. OBJECTIVE We sought to evaluate whether omalizumab(More)
  • 1